Thyroid Cancer Clinical Trial
Official title:
Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma
During surgery, a fine needle puncture was proceeded when suspicious nodes was found by clinician. Repeat the punction for 2-3 times from different orientation and then, Diff-quik staining or PTH immunochromatographic assay were proceeded for lymph node or parathyroid glands identification. Post-operative pathology outcome was considered as golden standard.
In the experiment group, when suspicious parathyroid glands or lymph nodes were observed, a
22 G needle was applied for in situ puncture at a 45 degree angle. The needle was initially
thrust into the gland for 0.2 mm, and then we advanced the needle for another 0.2mm while
gently withdrawing the plunger of the syringe and maintaining negative pressure. At this
point, there has parathyroid tissue been adsorbed in the needle. Repeat this process in two
different directions to guarantee the simple volume.
When cell smears finished, the smears were fixed in stationary liquid within 2-4 seconds for
5-20 seconds, and then Diff-Quik (DQ) staining technique was proceeded for rapid
identification using Diff-Quik staining kit according to the instruction. After the following
Diff-quick staining for 30 seconds, we can make out parathyroid cells and lymph nodes under
high power microscope.
In addition,PTH immunochromatographic assay kit can also be used for parathyroid glands
detection. Using indicator paper to dip to the punctured tissue, the existance of parathyroid
glands could be ensured.
HE (Hematoxylin and Eosin) staining was used for pathological verification of suspicious
nodes found during surgery. The suspicious nodes occurred in surgery were isolated and fixed
with 4% paraformaldehyde for 12 h, embedded in paraffin and cut into 3-µm serial sections.
Corresponding sections were stained with hematoxylin (BASO Diagnostics Inc. Zhuhai) for 10
min at room temperature. Then, sections were washed with running water. Subsequently,
sections were washed with Scott promote blue liquid for 1 min, 1% hydrochloric acid alcohol
differentiation liquid for 20 s, and Scott promote blue liquid for 1 min. Then, sections were
stained with eosin (BASO Diagnostics Inc. Zhuhai) for 30 s. Sections were washed with running
water and sealed for observation. Finally, sections were observed by Image-Pro Plus 5.0
software (Media Cybernetics, Inc., Bethesda, MD, USA).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |